Related Experiment Videos
Local therapy for cytomegalovirus retinitis
1Department of Pharmacy Practice, College of Pharmacy, Ferris State University, Lansing, MI, USA. Curtis_Smith@ferris.edu
The Annals of Pharmacotherapy
|March 13, 1998
Summary
Intraocular therapy offers an alternative for cytomegalovirus (CMV) retinitis in AIDS patients, but requires further research. While local treatments show promise, larger trials are needed to compare them with systemic therapies for CMV retinitis management.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Immunology
Background:
- Cytomegalovirus (CMV) retinitis is a significant opportunistic infection in individuals with Acquired Immunodeficiency Syndrome (AIDS).
- Systemic antiviral therapy has been the standard management, but carries potential toxicities and limitations.
- Intraocular therapy presents an alternative approach to directly target CMV retinitis in the eye.
Purpose of the Study:
- To evaluate the efficacy and role of intraocular (local) therapy in managing cytomegalovirus (CMV) retinitis in patients with AIDS.
- To compare the outcomes of intraocular treatments with traditional systemic therapies.
- To identify the advantages and disadvantages of different intraocular drug delivery methods.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE (1980-1997) and cross-referencing relevant articles.
- Data from randomized controlled trials and descriptive studies on local antiviral therapy for CMV retinitis were analyzed.
- Information on ongoing clinical trials was gathered from the AIDS/HIV Treatment Directory.
Main Results:
- Intravitreal ganciclovir (200-2000 micrograms weekly) showed initial effectiveness but was associated with high relapse rates and contralateral retinitis.
- Intraocular ganciclovir implants provided longer time to progression than intravenous therapy but increased risks of contralateral eye and extraocular CMV disease.
- Intravitreal foscarnet and cidofovir were also studied; cidofovir's long half-life suggests potential for infrequent dosing, pending further safety and efficacy data.
Conclusions:
- Systemic therapy remains the standard for CMV retinitis management in AIDS.
- Intraocular therapy presents both advantages and disadvantages, necessitating further investigation.
- Larger randomized controlled trials are crucial to definitively establish the role of local therapy compared to systemic treatment for CMV retinitis.